Novavax Inc. Stock
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | -1.570% | 4.326% | -10.354% | 56.387% | 151.691% | -94.444% | 84.079% |
| Evolus Inc | 0.690% | 8.209% | 15.079% | 72.619% | 60.221% | 116.418% | - |
| Ardelyx Inc. | 2.780% | -4.516% | -0.739% | 42.819% | -7.093% | 375.221% | 21.783% |
| Coherus Bioscien. | 6.000% | -12.403% | -10.907% | -75.986% | -66.546% | -93.220% | -94.772% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
Should You Buy Novavax Stock After This Regulatory Win?
Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
It's been a great year for Novavax (NASDAQ: NVAX). The biotech is up by 150% since January. However, analysts see even more upside for the vaccine maker. The consensus estimate of $20 a share